SCHEMBL5010387

SCHEMBL5010387

O=C(O)c1cc(NC(=O)c2sc3ccccc3c2Cl)[nH]n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.58
HDAC8 Q9BY41 1/20 0.58
HDAC6 Q9UBN7 1/20 0.58
NPC1 O15118 8/20 0.56
RAB9A P51151 8/20 0.56
MAPT P10636 8/20 0.56
SMN1; SMN2 Q16637 8/20 0.56
CTDSP1 Q9GZU7 1/20 0.56
PRSS12 P56730 7/20 0.55
MCL1 Q07820 1/20 0.55
OGG1 O15527 1/20 0.53
TP53 P04637 2/20 0.53
RXFP1 Q9HBX9 1/20 0.53
KDM4E B2RXH2 4/20 0.53
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
ALDH1A1 P00352 3/20 0.53
LMNA P02545 2/20 0.53
HPGD P15428 2/20 0.53
NFKB1 P19838 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5867678 0.81 NPC1 (0.55) HDAC1HDAC8HDAC6NPC1RAB9A
SCHEMBL14587857 0.80 KMT2A (0.64) HDAC1HDAC8HDAC6NPC1RAB9A
SCHEMBL5012062 0.80 CYTH3 (0.39) PRSS12MEN1KMT2A
SCHEMBL13659651 0.79 NPC1 (0.56) HDAC1HDAC8HDAC6NPC1RAB9A
SCHEMBL5935569 0.76 MAPT (0.79) HDAC1HDAC8HDAC6NPC1RAB9A
SCHEMBL4651922 0.76 MAPT (0.78) NPC1RAB9AMAPTSMN1; SMN2PRSS12
SCHEMBL5008289 0.75 CCNA2 (0.51) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL1886020 0.74 HDAC1 (1.00) HDAC1HDAC8HDAC6NPC1RAB9A
SCHEMBL5008226 0.74 CASP3 (0.45) NPC1RAB9AMAPTPRSS12MEN1
SCHEMBL10815290 0.73 NPC1 (0.62) HDAC1HDAC8HDAC6NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US claimed
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL HDAC1 1233/4885HDAC8 1901/4885HDAC6 1513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.